peptide
Mazdutide
emergingPhase 2/3 Clinical TrialsInjection
Dual GLP-1/glucagon receptor drug from Innovent Biologics. Strong weight loss and metabolic results. Already approved in China for obesity.
Key facts
- Classification
- Peptide — Dual GLP-1/glucagon receptor drug with strong weight loss results.
- Primary benefits
- Fat Loss (9/10) · Longevity (4/10) · Gut Health (4/10)
- Administration
- Injection
- Doses studied
- Start at a lower escalation dose and increase to 4-6 mg per week. The GLORY-1 trial tested 4 mg and 6 mg maintenance doses. Meant for long-term use.
- Evidence strength
- Emerging — 20 peer-reviewed studies
- Stacks well with
- 5-Amino-1MQ, MOTS-c, BPC-157
- Legal status
- Phase 2/3 Clinical Trials · not prescribable in US · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 3 peptides
- Regulatory
- Phase 2/3 Clinical Trials
Goal coverage · Mazdutide
🔥 Fat Loss9/10
⏳ Longevity4/10
🫃 Gut Health4/10
🧊 Inflammation3/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications